Eloxx Pharmaceuticals (ELOX) 10-K 13 Oct 17 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2017	Sep. 25, 2017	Dec. 31, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	Sevion Therapeutics, Inc.
Entity Central Index Key	1,035,354
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 2,520,758
Trading Symbol	SVON
Entity Common Stock, Shares Outstanding		51,414,613

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2017	Jun. 30, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 33,198	$ 810,808
Prepaid expenses and other current assets	251,223	171,820
Total Current Assets	284,421	982,628
Equipment, furniture and fixtures, net	50,979	92,554
Acquired research and development	5,500,000	8,100,000
Security deposits	9,800	50,770
TOTAL ASSETS	5,845,200	9,225,952
CURRENT LIABILITIES:
Accounts payable	191,597	90,305
Accrued expenses	330,301	256,376
Notes Payable	407,122	0
Derivative Liability	1,844,974	0
Other current liabilities	0	22,310
Total Current Liabilities	2,773,994	368,991
Warrant and Stock Right liabilities	0	956,575
Deferred tax liability	2,200,000	3,240,000
Other liabilities	0	99,728
TOTAL LIABILITIES	4,973,994	4,665,294
STOCKHOLDERS' EQUITY:
Common stock, $0.01 par value, authorized 500,000,000 shares, issued and outstanding 29,202,799 and 20,496,385 at June 30, 2017 and June 30, 2016 respectively	292,028	204,964
Capital in excess of par	122,401,918	119,983,399
Accumulated deficit	(121,824,326)	(115,630,059)
Total Stockholders' Equity	871,206	4,560,658
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	5,845,200	9,225,952
Series A Convertible Preferred stock
STOCKHOLDERS' EQUITY:
Convertible preferred stock	3	4
Series C Convertible Preferred stock
STOCKHOLDERS' EQUITY:
Convertible preferred stock	$ 1,583	$ 2,350

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Common stock, par value	$ 0.01	$ 0.01
Common stock, authorized	500,000,000	500,000,000
Common stock, issued	29,202,799	20,496,385
Common stock, outstanding	29,202,799	20,496,385
Series A Convertible Preferred Stock
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, shares issued	10,297	10,297
Preferred stock, shares outstanding	270	380
Preferred stock, liquidation preference	$ 280,418	$ 389,500
Series C Convertible Preferred stock
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	1,228,500	1,228,500
Preferred stock, shares issued	158,336	235,004
Preferred stock, shares outstanding	158,336	235,004
Preferred stock, liquidation preference	$ 1,583	$ 2,350

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Licensing Revenue	$ 0	$ 75,000	$ 75,000
Operating expenses:
General and administrative	1,408,936	1,606,043	3,170,499
Research and development	733,661	2,182,989	4,568,435
Gain on sale of patents	(149,728)	0	0
Impairment of goodwill	0	5,780,951	8,121,966
Impairment of acquired R&D	2,600,000	1,700,000	0
Impairment and write-off of patents	0	0	2,290,836
Total operating expenses	4,592,869	11,269,983	18,151,736
Loss from operations	(4,592,869)	(11,194,983)	(18,076,736)
Other non-operating income (expense)
Change in fair value of stock right	651,484	254,027	12,405
Change in fair value of warrant liability	249,025	1,993,560	3,313
Change in fair value of note derivitive	(1,175,522)
Stock issuance for anti dilution right	(1,417,922)	0	0
Modification of warrant exercise price	(285,356)
Interest expense	(265,203)	(533)	(2,767)
Net loss before income tax benefit	(6,836,363)	(8,947,929)	(18,063,785)
Income tax benefit	1,040,000	680,000	0
Net Loss	(5,796,363)	(8,267,929)	(18,063,785)
Preferred dividends	(397,904)	(179,154)	(838,925)
Net loss available to common shares	$ (6,194,267)	$ (8,447,083)	$ (18,902,710)
Basic and diluted net loss per common share	$ (0.27)	$ (0.42)	$ (1.31)
Basic and diluted weighted-average number of common shares outstanding	23,219,237	20,322,714	14,417,029

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Total	Preferred stock	Common Stock	Capital in Excess of Par Value	Accumulated Deficit
Beginning Balance at Jun. 30, 2014	$ 27,489,929	$ 6	$ 138,463	$ 115,631,726	$ (88,280,266)
Beginning Balance (in shares) at Jun. 30, 2014		580	13,846,361
Stock-based compensation	480,681	$ 0	$ 0	480,681	0
Stock-based compensation (in shares)		0	0
Preferred stock converted into common stock	0	$ (2)	$ 1,000	(998)	0
Preferred stock converted into common stock (in shares)		(200)	100,000
Deemed dividend - preferred stock	0	$ 0	$ 0	790,507	(790,507)
Dividends paid	14,500	$ 0	$ 595	55,988	(42,083)
Dividends paid (in shares)		0	59,500
Dividends accrued and unpaid	(6,335)	$ 0	$ 0	0	(6,335)
Stock issued for Cash	4,827,569	$ 2,358	$ 47,470	4,777,741	0
Stock issued for Cash (in shares)		235,837	4,746,952
Warrant Liability	(1,742,703)	$ 0	$ 0	(1,742,703)	0
Derivative Stock Right	(775,062)	0	0	(775,062)	0
Net loss	(18,063,785)	0	0	0	(18,063,785)
Ending Balance at Jun. 30, 2015	12,224,794	$ 2,362	$ 187,528	119,217,880	(107,182,976)
Ending Balance (in shares) at Jun. 30, 2015		236,217	18,752,813
Stock-based compensation	156,678	$ 0	$ 0	156,678	0
Stock-based compensation (in shares)		0	0
Preferred stock converted into common stock	0	$ (675)	$ 6,750	(6,075)	0
Preferred stock converted into common stock (in shares)		(67,500)	675,000
Deemed dividend - preferred stock	0	$ 0	$ 0	135,701	(135,701)
Dividends paid	6,335	$ 0	$ 1,086	39,200	(33,951)
Dividends paid (in shares)		0	108,576
Dividends accrued and unpaid	(9,502)	$ 0	$ 0	0	(9,502)
Stock issued for Cash	1,152,397	$ 667	$ 9,600	1,142,130	0
Stock issued for Cash (in shares)		66,667	959,996
Warrant Liability	(559,261)	$ 0	$ 0	(559,261)	0
Derivative Stock Right	(142,854)	0	0	(142,854)	0
Net loss	(8,267,929)	0	0	0	(8,267,929)
Ending Balance at Jun. 30, 2016	4,560,658	$ 2,354	$ 204,963	119,983,399	(115,630,059)
Ending Balance (in shares) at Jun. 30, 2016		235,384	20,496,385
Stock issued for convertible debt	268,377	$ 0	$ 10,322	258,055	0
Stock issued for convertible debt (in shares)			1,032,219
Stock issued due to antidilution	1,417,922		$ 56,717	1,361,205	0
Stock issued due to antidilution (in shares)			5,671,689
Warrant modification	285,356	0	$ 0	285,356	0
Reclass warrant from liability to equity	56,066			56,066	0
Stock-based compensation	80,108	$ 0	$ 0	80,108	0
Stock-based compensation (in shares)		0	0
Preferred stock converted into common stock	0	$ (768)	$ 17,900	(17,132)	0
Preferred stock converted into common stock (in shares)		(76,778)	1,790,024
Deemed dividend - preferred stock			$ 0	354,389	(354,389)
Dividends paid	9,502		$ 2,125	40,472	(33,096)
Dividends paid (in shares)			212,482
Dividends accrued and unpaid	(10,419)	$ 0	$ 0	0	(10,419)
Net loss	(5,796,363)	0	0	0	(5,796,363)
Ending Balance at Jun. 30, 2017	$ 871,206	$ 1,586	$ 292,028	$ 122,401,918	$ (121,824,326)
Ending Balance (in shares) at Jun. 30, 2017		158,606	29,202,799

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (5,796,363)	$ (8,267,929)	$ (18,063,785)
Noncash (income) expense related to change in fair value of:
stock right	(651,484)	(254,027)	(12,405)
warrant liability	(249,025)	(1,993,560)	(3,313)
Derivative liability	1,175,522
Noncash charge for change in warrant terms	285,356
Noncash charge for common stock antidilution issuance	1,417,922	0	0
Noncash charge for accretion of debt discount	241,730
Gain on sale of patents	(149,728)	0	0
Stock-based compensation expense	80,108	156,678	480,681
Depreciation and amortization	44,075	93,394	177,074
Loss on Disposal of Assets	0	0	8,071
Impairment of goodwill	0	5,780,951	8,121,966
Write-off of intangibles	2,600,000	1,700,000	2,290,836
Deferred Tax	(1,040,000)	(680,000)	0
Write-off of prepaid research supplies	0	0	669,750
Deferred rent	(22,310)	(62,778)	85,088
(Increase) decrease in operating assets:
Prepaid expenses and other current assets	(79,403)	223,280	48,208
Security deposit	40,970	0	(45,599)
Increase (decrease) in operating liabilities:
Accounts payable	101,292	(141,728)	(669,147)
Accrued expenses	76,228	(155,496)	(507,121)
Deferred revenue	0	(75,000)	75,000
Net cash used in operating activities	(1,925,110)	(3,676,215)	(7,344,696)
Cash flows from investing activities:
Proceeds from sale of patents	50,000	0	0
Capitalized Patent costs	0	0	(136,946)
Purchase of equipment, furniture and fixtures	(2,500)	0	(122,641)
Net cash provided by (used in) investing activities	47,500	0	(259,587)
Cash flows from financing activities:
Proceeds from issuance of convertible notes	1,100,000	0	0
Proceeds from issuance of common stock and warrants, net and exercise of warrants and options	0	1,152,397	4,827,569
Net cash provided by financing activities	1,100,000	1,152,397	4,827,569
Net (decrease) increase in cash and cash equivalents	(777,610)	(2,523,818)	(2,776,714)
Cash and cash equivalents at beginning of period	810,808	3,334,626	6,111,340
Cash and cash equivalents at end of period	33,198	810,808	3,334,626
Supplemental disclosure of non-cash transactions:
Conversion of convertible note plus accrued interest into common stock	268,377	0
Conversion of preferred stock into common stock	17,900	6,750	998
Allocation of equity proceeds to warrants	0	559,261	1,742,703
Allocation of equity proceeds to stock rights	0	142,854	775,062
Allocation of preferred stock proceeds to beneficial conversion feature	0	135,701	790,507
Allocation of convertible note proceeds to derivative liability	1,101,413	0	0
Issuance of common stock for interest payments on convertible notes	42,597	40,286	56,583
Issuance of common stock for dividend payments on preferred stock	0	0	0
Issuance of common stock in settlement of accounts payable	10,419	9,502	6,335
Reclass warrant liability to equity	56,066	0	0
Deemed dividend - preferred stock	354,389	0	0
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 0	$ 0	$ 137

Principal Business Activity

Principal Business Activity	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Principal Business Activity	1. Principal Business Activity: The Company Sevion Therapeutics, Inc. (the “Company”), which includes the accounts of Senesco Inc., a New Jersey corporation (“SI”), Fabrus, Inc., a Delaware corporation (“Fabrus”) and Sevion Sub Ltd., an Israeli company (“Acquisition Sub”), is a development-stage biotech company developing a portfolio of innovative therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The antibody approach is a novel discovery paradigm with the proven capability to identify functional therapeutic monoclonal antibodies against challenging cell surface targets that previously have been highly resistant to therapeutic antibody discovery. The Company has several antibodies in the Company’s preclinical pipeline. The first to move forward is a potentially first/best in class candidate antibody that targets an ion channel important in autoimmunity and inflammation. On May 31, 2017, the Company entered into an agreement (the “Agreement”), which was amended on August 1, 2017, with Sevion Acquisition Co. Ltd., an Israeli company and the Company’s wholly-owned subsidiary (“Acquisition Subsidiary”), and Eloxx Pharmaceuticals Ltd., an Israeli company (“Eloxx”), pursuant to which Eloxx will merge with and into Acquisition Subsidiary, with Eloxx surviving as the Company’s wholly-owned subsidiary (the “Transaction”). Consummation of the Transaction is subject to certain closing conditions, including, among other things: (i) approval of the Transaction by the stockholders of Eloxx; (ii) the successful consummation of separate equity financings resulting in cash investments in the Company’s business and Eloxx of no less than $ 12,000,000 312,260 Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). Liquidity The financial statements of the Company have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Accordingly, the financial statements do not include any adjustments that might be necessary should the Company be unable to continue in existence. The Company has not generated substantial revenues and has not yet achieved profitable operations. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, and commercialization of the Company’s products will require significant additional financing. The Company’s accumulated deficit at June 30, 2017 totaled $ 121,824,326 On October 22, 2014, the Company’s board of directors decided to suspend all development of the Company’s Factor 5A technology based on the Company’s limited capital resources and the totality of the safety and efficacy data resulting from the Phase 1b/2a clinical trial. The board of directors also decided to close the Company’s Bridgewater, New Jersey office in order to consolidate all of the Company’s operations in its San Diego, California location and terminated its research agreement with the University of Waterloo. In connection with these changes, the Company paid $ 47,000 In addition, given the Company’s limited capital resources, in December 2014, the Company decided to temporarily reduce its research and development spending on the Company’s antibody program. On May 31, 2017, the Company entered into an Agreement to acquire Eloxx Pharmaceuticals Ltd., an Israeli company for stock. Consummation of the Transaction is subject to certain closing conditions, including, among other things: (i) approval of the Transaction by the stockholders of Eloxx; (ii) the successful consummation of equity financings resulting in cash investments in each of the Company and Eloxx of no less than $ 12,000,000 As of June 30, 2017, the Company had cash in the amount of $ 33,198 1,500,000 The historical operating results indicate substantial doubt exists related to the Company’s ability to continue as a going concern. Presently, with no further financing, the Company projects that its current cash balance will allow it to operate in the normal course of business until December 31, 2017. While the Company believes that consummation of the Transaction would mitigate the substantial doubt raised by its historical operating results and allow the Company to continue its current operations as a going concern for at least the next 12 months, the Company cannot predict with certainty whether the Transaction will be successfully completed or if the proceeds received from the fulfillment of its Financial Covenant will be sufficient to allow it to continue its current operations as a going concern. If the Company is unable to raise additional funds or complete the Transaction, it will need to do one or more of the following: ⋅ license third parties to develop and commercialize products or technologies that it would otherwise seek to develop and commercialize itself; ⋅ seek strategic alliances or business combinations; ⋅ attempt to sell the Company; ⋅ cease operations; or ⋅ declare bankruptcy. Risks and Uncertainties The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company's operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure. The Company’s limited capital resources and operations to date have been funded primarily with the proceeds from public and private equity and debt financings and milestone payments on license agreements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies	2. Summary of Significant Accounting Policies: The accompanying consolidated financial statements include the accounts of Sevion Therapeutics, Inc. and the Company’s wholly owned subsidiaries, Senesco Inc., Fabrus, Inc. and Sevion Sub Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock-based compensation expense, warrant, derivatives and stock rights liabilities, the determination of the fair value of equity transactions and stock-based awards, the accounting for research and development costs, the accounting for impairment and accrued expenses. The Company considers all highly liquid instruments with an original maturity of 90 ASC Topic 820, Fair Value Measurements, defines fair value, establishes a framework for measuring fair value and expands the related disclosure requirements. The guidance applies under other accounting pronouncements that require or permit fair value measurements. The statement indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. ASC 820 defines fair value based upon an exit price model. The Company categorizes the Company’s financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial assets recorded at fair value on the Company’s consolidated balance sheets are categorized as follows: • Level 1: Observable inputs such as quoted prices in active markets; • Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and • Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Level 3 financial instruments consist of common stock warrants with an exercise reset feature, derivatives which are conversion features in the Convertible Notes (Note 7), and common stock with embedded anti-dilutive features (“Rights”). The fair value of these warrants and Rights are estimated using a Monte Carlo valuation model, and the derivatives are valued using a weighted average Black Scholes method. The unobservable input used by the Company was the estimation of the likelihood of a reset occurring on the warrants and the anti-dilutive Rights. These estimates of the likelihood of completing an equity raise that would meet the criteria to trigger the reset provisions and anti-dilutive Rights are based on numerous factors, including the remaining term of the financial instruments and the Company’s overall financial condition. (See Note 8). The inputs used in the Black Scholes model include fair value of the common stock, interest rate, volatility of the Company’s stock and expected remaining term. The carrying value of prepaid expenses, accounts payable and accrued expenses reported in the consolidated balance sheets equal or approximate fair value due to their short maturities. Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains cash balances at financial institutions, which at times, exceed federally insured limits. At June 30, 2017 the Company’s cash amount did not exceed FDIC insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash. Equipment, furniture and fixtures are recorded at cost, except for the equipment acquired in the acquisition of Fabrus, which is recorded at fair value. Depreciation is calculated on a straight-line basis over three to four years for office equipment, five years for lab equipment and five to seven years for furniture and fixtures. Expenditures for major renewals and improvements are capitalized, and expenditures for maintenance and repairs are charged to operations as incurred. (See Note 4). Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized, but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company wrote off its remaining goodwill balance in the fiscal year ended June 30, 2016 as a result of an impairment review. Intangible assets include in-process research and development (IPR&D) of pharmaceutical product candidates. IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss on the Company’s consolidated statement of operations. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. For the year ended June 30, 2017, the Company determined that there was impairment to IPR&D. (See Note 5) The Company assesses the impairment in long-lived assets whenever events or circumstances indicate that their carrying value may not be recoverable. Factors the Company considers important which could trigger an impairment review include the following: • significant negative industry trends; • significant underutilization of the assets; • significant changes in how the Company uses the assets or its plans for their use; and • changes in technology and the appearance of competing technology. If a triggering event occurs and if the Company's review determines that the future undiscounted cash flows related to the groups, including these assets, will not be sufficient to recover their carrying value, the Company will reduce the carrying values of these assets down to their estimated fair value. The Company recorded impairment of long lived assets of $ 0 0 2,290,836 Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of the Company’s common stock outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional shares of Common Stock that would have been outstanding if the potential shares of Common Stock had been issued and if the additional shares of Common Stock were dilutive. For all periods presented, basic and diluted loss per share are the same, as any additional Common Stock equivalents would be anti-dilutive. June 30, 2017 2016 Common Stock to be issued upon conversion 1,080,000 506,666 Common Stock to be issued upon conversion 2,968,801 2,350,040 Common Stock to be issued upon conversion of convertible notes and accrued interest 10,234,000 - Outstanding warrants 5,011,591 8,698,580 Outstanding options 2,319,267 1,917,238 Total potentially dilutive shares of Common Stock 21,613,659 13,472,524 Income taxes are recorded in accordance with ASC Topic 740, Income Taxes, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of June 30, 2017, the Company’s tax years prior to June 30, 2014 are no longer subject to examination by the tax authorities. The Company is not currently under examination by any U.S. federal or state jurisdictions. As of June 30, 2017 and 2016, the Company does not have any significant uncertain tax positions. The Company has received certain nonrefundable upfront fees in exchange for the transfer of the Company’s technology to licensees. Upon delivery of the technology, the Company had no further obligations to the licensee with respect to the basic technology transferred and, accordingly, recognized revenue at that time. The Company has received certain nonrefundable upfront license fees in connection with agreements that include time-based payments and are deferred and amortized ratably over the estimated research period of the license. The Company has and may continue to receive additional payments from the Company’s licensees in the event such licensees achieve certain development or commercialization milestones in their particular field of use. Milestone payments, which are contingent upon the achievement of certain research goals, are recognized as revenue when the milestones, as defined in the particular agreement, are achieved. The Company accounts for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. For stock options issued to employees, the Company estimates the grant-date fair value of each option using the Black-Scholes option-pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates, the value of the common stock and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense, net of estimated forfeitures, equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. For awards subject to both performance and service-based vesting conditions, the Company recognizes stock-based compensation expense using the straight-line recognition method when it is probable that the performance condition will be achieved. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based payments issued to non-employees are recorded at their fair values, and are periodically revalued as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. Fiscal Year Ended June 30, 2017 2016 2015 General and administrative $ 73,707 $ 130,186 $ 401,411 Research and development 6,401 26,492 79,270 Total $ 80,108 $ 156,678 $ 480,681 Fiscal Year Ended June 30, 2017 2016 2015 Risk-free interest rate (1) 1.98% .00% - 2.15% 0.02%-2.32% Expected volatility 106.00% 69%-146% 95%-153% Dividend yield None None None Expected life (in years) (2) 5.0 .08 - 8.4 0.63 - 10.0 (1) Represents the interest rate on a U.S. Treasury security with a maturity date corresponding to that of the option term. (2) Expected life for employee based stock options was estimated using the “simplified” method, as allowed under the provisions of the Securities and Exchange Commission Staff Accounting Bulletin No. 110. Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses, including salaries, benefits and travel and stock-based compensation of the Company’s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct preclinical studies; other supplies; allocated facilities, depreciation and other expenses, which include rent and utilities; insurance; and costs associated with preclinical activities and regulatory operations. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In May 2014, the FASB issued ASU No. 2014- 09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 requires that a company recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which the company expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. In July 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is in the process of evaluating the effect of adoption. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” (“ASU 2014-15”). ASU 2014-15 amended existing guidance related to the disclosures about an entity’s ability to continue as a going concern. These amendments are intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. These amendments provide guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the financial statement footnotes. The amendments are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. The Company has adopted this standard and there was no material impact on the consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes FASB ASC 840. All entities will be required to record operating leases on the balance sheet as assets and liabilities instead of recording only capital (finance) leases on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2017. The Company s in the process of evaluating the effect of adoption. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share Based Payment Accounting,” which is intended to simplify several aspects of accounting for share based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted. The Company does not anticipate that the adoption of this standard will have a material impact on the Company’s financial statements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments, which addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows under Accounting Standards Codification 230. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those fiscal years. Early application is permitted. The Company does not anticipate that the adoption of this standard will have a material impact on the Company’s financial statements. In July 2017, the FASB issued ASU No. 2017-11, which amends the FASB Accounting Standards Codification. Part I of ASU No. 2017-11, Accounting for Certain Financial Instruments with Down Round Features, changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The guidance is effective for reporting periods beginning after December 15, 2019 and interim periods within those fiscal years. The Company is in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements. The Company has assessed other recently issued accounting pronouncements and has determined that they do not apply.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements: Carrying Fair Value Measurement at June 30, 2017 Value Level 1 Level 2 Level 3 Cash and cash equivalents $ 33,198 $ 33,198 $ - $ - Derivative Liability $ 1,844,974 $ - $ - $ 1,844,974 Carrying Fair Value Measurement at June 30, 2016 Value Level 1 Level 2 Level 3 Cash and cash equivalents $ 810,808 $ 810,808 $ - $ - Warrant and Stock Right Liabilities $ 956,575 $ - $ - $ 956,575 Fiscal Year ended June 30, 2017 2016 Beginning Balance $ 956,575 $ 2,502,047 Allocation of convertible note proceeds to derivative liability 1,101,413 - Change in fair value of derivative liability 743,561 - Issuance of common stock warrants - 559,261 Recognition of stock right - 142,854 Reclass to equity (56,066) - Change in fair value of warrant liabilities, net (249,025) (1,993,560) Change in fair value of stock right, net (651,484) (254,027) Ending Balance $ 1,844,974 $ 956,575 See Note 8 for additional information.

Equipment, Furniture and Fixtur

Equipment, Furniture and Fixtures	12 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Equipment, Furniture and Fixtures	4. Equipment, Furniture and Fixtures: June 30, 2017 2016 Laboratory Equipment $ 313,023 $ 310,523 Office Equipment 15,569 21,680 Leasehold Improvements - 10,236 Furniture and fixtures 3,700 6,920 $ 332,292 $ 349,359 Less—Accumulated depreciation (281,313) (256,805) $ 50,979 $ 92,554 Depreciation expense aggregated $ 44,075 93,394 152,097 19,567

Intangible assets

Intangible assets	12 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets	5. Intangible assets: In December 2014, as a result of the decrease in the market value of the Company, the Company determined that there was a triggering event that required the Company to review if there had been an impairment to the Acquired Research and Development in the amount of $ 9,800,000 283,393 13,902,917 8,121,966 As of June 30, 2015 the Company performed a review to determine if there was impairment to the Acquired Research and Development and Goodwill as of that date. The Company first evaluated the Acquired Research and Development for impairment by reviewing the assumptions utilized in establishing the value allocated to the Acquired Research and Development. Based on the evaluation, the Company determined that no impairment exists. The Company then evaluated its Goodwill using its market capitalization in determining the amount of the impairment. The Company concluded that there was no additional impairment beyond what had been recorded at December 31, 2014. As a result of the further decrease in the market value of the Company, the Company determined that there was a triggering event that required the Company to review if there had been an impairment to the Acquired Research and Development and Goodwill as of December 31, 2015. The Company first evaluated the Acquired Research and Development for impairment by reviewing the assumptions utilized in establishing the value allocated to the Acquired Research and Development. Based on the evaluation, the Company determined that no impairment exists. The Company then evaluated its Goodwill. The Company’s evaluation used its market capitalization plus a control premium (which is considered a level 2 input in the fair value hierarchy) in determining the amount of the impairment. The Company concluded that there was an impairment based on the significant change in the Company’s market value during the period. As a result of this evaluation, the Company determined that the Goodwill was impaired and recorded an impairment charge in the amount of $ 2,800,000 For the quarter ended March 31, 2016, as a result of the significant further decrease in the market value of the Company, the Company determined that there was a triggering event that required the Company to review if there had been an impairment to the Acquired Research and Development and Goodwill. For the Acquired Research and Development the Company updated the discounted cash flow analysis and reviewed the input assumptions which were the basis for the valuation performed as of May 14, 2014 (Date of Acquisition). Updates were made to the inputs based upon industry knowledge and management experience which affected future revenue streams, timing and probabilities. Based on the evaluation, the Company determined that an impairment existed. In addition, due to the significant drop in market value which the company experienced in the period, the company evaluated the market for the Acquired Research & Development. As a result of this evaluation, the Company determined that the intangible was impaired and market value would approximate $ 8.8 1,000,000 2,981,000 As of June 30, 2016 the Company performed a review to determine if there was impairment to the Acquired Research and Development as of that date. The Company first evaluated the Acquired Research and Development for impairment by reviewing the assumptions utilized in establishing the value allocated to the Acquired Research and Development which had been updated from the previous quarter. Based on the evaluation, the Company determined that an impairment existed. The Company measured the enterprise value for purposes of the Step 2 measurement of Intangibles. The Company concluded that there was an impairment based on the significant change in the Company’s market value during the period. As a result of this evaluation, the Company determined that there was an additional impairment to the Acquired Research and Development as of June 30, 2016 in the amount of $ 700,000 During each of the quarters ended September 30, 2016 and December 31, 2016, as a result of the significant further decrease in the market value of the Company, the Company determined that there was a triggering event that required the Company to review if there had been an impairment to the Acquired Research and Development. Based on the evaluation, the Company determined that an impairment existed. The Company measured the enterprise value for purposes of the Step 2 measurement of Intangibles. The Company concluded that there was an impairment based on the significant change in the Company’s market value during the quarters. As a result of these evaluations, the Company determined that there was impairment to the Acquired Research and Development as of September 30, 2016 and December 31, 2016 in the amount of $ 1,600,000 1,000,000 As of June 30, 2017 the Company performed a review to determine if there was impairment to the Acquired Research and Development as of that date. The Company measured the enterprise value for purposes of the Step 2 measurement of Intangibles. The Company concluded that there was no additional impairment based on the Company’s market value. In October 2014, the Company decided to continue to develop its intellectual property only with respect to the human health therapeutic targets and would be reviewing such patents on a patent by patent basis to determine which specific ones to continue to develop. Also, in October 2014, the Company decided to suspend all development of the Factor 5A technology based on the Company’s limited capital resources and the totality of the safety and efficacy data resulting from our Phase 1b/2a clinical trial. As the Company was unable to determine if or when the development would be resumed, the Company was unable to determine what the future undiscounted cash flows from these patents could be. Therefore, the Company determined that the carrying value of its patents and patent applications related to Factor 5A were impaired. Accordingly, the Company recorded an impairment of the full carrying value of its patents related to Factor 5A in the amount of $ 2,290,836 Additionally, during the quarter ended September 30, 2014, the Company concluded its Phase 1b/2a clinical trial but did not use all of the material purchased for the clinical trial. As the Company has put the clinical program for this product candidate on hold, the Company wrote-off the cost of the remaining material in the amount of $ 669,750

Accrued Expenses

Accrued Expenses	12 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Accrued Expenses	6. Accrued Expenses: June 30, 2017 2016 Accrued research $ - $ 66,409 Accrued professional fees 200,000 - Accrued interest 20,178 - Accrued payroll 66,200 74,240 Accrued dividends payable 10,418 9,502 Accrued other 33,505 106,225 $ 330,301 $ 256,376

Notes Payable

Notes Payable	12 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Notes Payable	7. Notes Payable: On November 10, 2016, the Company entered into unsecured promissory notes (the “November Notes”) in the aggregate amount of $ 300,000 5 The Company subsequently issued convertible promissory notes on February 15, 2017 (the “February Notes”) and May 22, 2017 (the “May Notes”, and together with the February Notes, the “2017 Notes”), in the aggregate amount of $ 800,000 6 The 2017 Notes provide for mandatory conversion: (a) if the Company enters into a transaction or series of transactions for an aggregate sale price of at least One Million Dollars ($1,000,000) of the Company’s capital stock (referred to as the “Qualified Financing”) then the outstanding principal balance and accrued but unpaid interest on the 2017 Notes will automatically convert into such capital stock sold in the Qualified Financing at a conversion price equal to the lesser of (i) the price per share paid by investors at the close of the Qualified Financing or (ii) $ 0.10 In connection with the issuance of the 2017 Notes, the Company also amended and restated the November Notes in order to make them convertible upon the same terms as the 2017 Notes, including the conversion features detailed above (collectively, the “Convertible Notes”). The Company analyzed guidance in ASC 470, Debt, and determined that the modification of the November Notes met the definition of a Troubled Debt Restructuring because the noteholders granted a concession to the Company. Based on the guidance for Troubled Debt Restructuring, the amended November Notes are accounted for prospectively from the time of restructuring. The carrying amount is not changed, and a new effective interest rate is calculated to accrete the amended notes back to its principal and related interest amount through the maturity date of November 10, 2017 Notwithstanding the above, the Convertible Notes contain a blocker feature which does not allow for conversion if it would cause such purchaser’s beneficial ownership of the shares of capital stock of any class of the Company outstanding at the time of conversion to exceed 4.99 9.99 The embedded conversion features in Convertible Notes are bifurcated and accounted for separately under the guidance for derivative accounting in ASC 815 and ASC 480. A liability of the fair value of the derivatives was recorded as of the original issuance date of the Convertible Notes, and any changes in the fair value at each financial statement date are recorded in the statement of operations of the consolidated financial statements. Convertible Notes are recorded at amortized cost, net of debt discount, and accreted using the effective interest method over the term of the Convertible Notes. February 15, 2017 March 31, 2017 May 22, 2017 June 30, 2017 Fair Value of Common Stock $ 0.15 0.25 $ 0.15 0.19 $ 0.26 $ 0.27 Exercise Price $ 0.10 $ 0.10 $ 0.10 $ 0.10 Expected Term (years) 0.17 0.75 0.17 0.63 0.33 0.50 $ 0.13 0.39 Volatility 173.5 214.5 160 178.8 155.1 174.6 103.8 146.7 Risk Free Interest Rate 0.54 0.77 0.76 0.94 0.97 1.05 0.84 1.09 The Company estimated the fair value of the derivative liability related to the May Notes which was greater than the proceeds received. According to the guidance from the SEC in the 2014 AICPA conference, management recorded a loss of $ 212,000 On June 1, 2017, Convertible Notes with principle amount of $ 100,000 3,222 1,032,219 54,000

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity: Series A Preferred Stock Each share of Series A Convertible Preferred Stock has a stated value of $ 1,000 10 If the dividends are paid in shares of Common Stock, such shares will be priced at the lower of 90% of the average volume weighted-average price for the 20 trading days immediately preceding the payment date. Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary, the Holders shall be entitled to receive an amount equal to the Stated Value plus any accrued and unpaid dividends and any other fees or liquidated damages then due and owing thereon for each share of Series A Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities. If the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the Holders shall be ratably distributed among the Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full. During the fiscal years ended June 30, 2017, 2016 and 2015, a total of 212,482 108,576 59,500 42,598 40,286 56,583 The shares of Series A Convertible Preferred Stock were convertible into shares of Common Stock at an initial conversion price of $ 32.00 The conversion price was subject to adjustment if the Company sells or grants any Common Stock or Common Stock equivalents, subject to certain exclusions, at an effective price per share that was lower than the conversion price of the Series A Convertible Preferred Stock. As a result of multiple issuances of shares of common stock and the Exchange Agreement (defined below), the initial conversion prices had been adjusted from $32.00 per share to $0.25 per share. On February 15, 2017, in connection with the issuance of the Notes (see Note 7), certain of the holders of the Company’s outstanding Series A Preferred Stock exchanged 110 440,000 0.25 270 138 The shares of Common Stock issued pursuant to the Exchange Agreement were issued solely to former holders of Series A Preferred Stock, upon exchange pursuant to the exemption from registration provided under Section 3(a)(9) of the Securities Act. This exemption is available to the Company because the shares of Common Stock were exchanged by the Company with its existing security holders with no commission or other remunerations being paid or given for soliciting such an exchange. Series C Preferred Stock Each share of 0 7.50 0.75 4.99 The Series C Preferred Stock is entitled to receive dividends (on an as-converted to Common Stock basis) to and in the same form as dividends actually paid on shares of Common Stock and are entitled to the number of votes equal to the number of shares of Common Stock issuable upon conversion of the Series C Preferred Stock, subject to beneficial ownership limitations on conversion. Holders of Series C Preferred Stock shall vote together with the holders of Common Stock and not vote as a separate class. In connection with a liquidation event, any payment due on the Series C Preferred Stock shall be made payable prior to, and in preference of, any Common Stock. In addition, if the Company grants options, purchase rights or other securities to all existing holders of Common Stock, other than certain exempt issuances, the holders of the Series C Preferred Stock have the right to purchase such number of shares of Common Stock that would have been provided to such holder if such holder held the number of shares of Common Stock underlying the Series C Preferred Stock. Upon the liquidation, dissolution or winding up of the business of the Company, whether voluntary or involuntary, each holder of Series C Preferred Shares shall be entitled to receive a preferential amount in cash equal to the Par Value. All preferential amounts to be paid to the holders of Series C Preferred Shares shall be paid before the payment or setting apart for payment of any amount for, or the distribution of any assets of the Company to the holders of (i) any other class or series of capital stock whose terms expressly provide that the holders of Series C Preferred Shares should receive preferential payment with respect to such distribution (to the extent of such preference) and (ii) the Common Stock but not before any payment to holders of outstanding shares of the Company’s Series A Preferred Stock. If upon any such distribution the assets of the Company shall be insufficient to pay the holders of the Series C Preferred Shares the full amounts to which they shall be entitled, such holders shall share ratably in any distribution of assets in accordance with the sums which would be payable on such distribution if all sums payable thereon were paid in full. Public Placements of Series C Preferred Stock, Common Stock and Warrants In May, June and July, 2015, the Company sold units of its securities (the “Units”) with each Unit consisting of one share of the Company’s common stock or, at the election of the Investor, shares of the Company’s newly designated 0% Series C Convertible Preferred Stock (the “Series C Preferred Stock”) and a warrant to purchase one half of one share of Common Stock at an exercise price of $ 1.50 0.75 4,746,952 2,358,370 235,837 2,358,370 3,552,640 5,328,966 501,397 1,626,663 666,667 66,667 666,667 813,332 1,219,997 67,600 On the closing date (July 27, 2015) the Placement Agent was issued 555,552 0.75 The warrants are entitled to be exercised at any time on or after the issuance date and on or prior to the close of business on the thirty month anniversary of their issuance. The initial exercise price per share of the Common Stock under the Warrants and the Placement Agent Warrants shall be $ 1.50 0.75 The Company first allocated the proceeds from the offering to the warrants based upon the fair value of the warrant which amounted to $ 1,742,703 559,261 3,313 1,993,560 249,025 56,066 The warrant liabilities represent the fair value of Common Stock purchase warrants which have exercise price reset features estimated using a Monte Carlo valuation model. The Company computes a valuation using the Monte Carlo model for such warrants to account for the various possibilities that could occur due to changes in the inputs to the model as a result of contractually-obligated changes. These estimates of the likelihood of completing an equity raise that would meet the criteria to trigger the reset provisions are based on numerous factors, including the remaining term of the financial instruments and the Company’s overall financial condition. Changes in the unobservable input values would likely cause material changes in the fair value of the Company’s Level 3 financial instruments. The significant unobservable input used in the fair value measurement was the estimation of the likelihood of the occurrence of a change to the strike price of the warrants. A significant increase (decrease) in this likelihood would have resulted in a higher (lower) fair value measurement. May/June 2015 Issuance 30-Jun-15 July 2015 Issuance 30-Jun-16 Estimated life in years 2.5 2.4 2.5 1.4 - 1.5 Risk-free interest rate (1) 0.73% 0.73% 0.91% 0.64% Volatility 115.20% 115.20% 108.60% 110.90% Dividend paid None None None None (1) Represents the interest rate on a U.S. Treasury security with a maturity date corresponding to that of the warrant term. In connection with the purchase of units, for a period beginning on the closing date (July 27, 2015) and ending on the date that is the earlier of 18 months from the closing date and the date the Company’s Common Stock is listed for trading on a national securities exchange, subject to certain restrictions as outlined in the agreement, if at any time the Company shall issue any Common Stock or securities convertible into or exercisable for shares of Common Stock (or modify any of the foregoing which may be outstanding) at a price per share or conversion or exercise price per share which shall be less than $ 0.75 0.01 Derivatives and Hedging-Contracts in Entity’s Own Equity, 775,062 142,854 12,405 254,027 651,484 The fair value of the right is estimated using a Monte Carlo model. The unobservable input used by the Company was the estimation of the likelihood of a reset occurring on the warrants and the anti-dilutive Rights. These estimates of the likelihood of completing an equity raise that would meet the criteria to trigger the reset provisions and anti-dilutive Rights are based on numerous factors, including the remaining term of the financial instruments and the Company’s overall financial condition. In connection with allocation of the gross proceeds to the issuance of the Series C Preferred Stock, the Company determined that the Preferred Stock’s conversion feature was considered to be beneficial. A beneficial conversion feature requires the Company to record a deemed dividend for a non-detachable conversion feature that is in the money at the issuance date. As a result, the Company recorded a deemed dividend amounting to $ 790,507 135,701 In accordance with the Registration Rights agreement, the Company was required to file a registration statement covering the registrable security for an offering to be made on a continuous basis pursuant to Rule 415 within 45 days from the final closing, and to be declared effected no later than 120 days from the final closing date. The agreement included a penalty of 1% per month of the investor’s investment, payable in cash, for every 30 day period up to a maximum of 6% for failure to comply with the terms of the agreement. In addition, the Company would take all commercially reasonable action necessary to continue the listing or quotation and trading of its Common Stock on a principal market for as long as any subscriber holds securities, and would comply in all material respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the principal market at least until five years after the closing date. In the event the listing is not continuously maintained for five years after the closing date, on each monthly anniversary of each such listing default date until the applicable listing default is cured, the Company would pay to each subscriber an amount in cash, as partial liquidated damages equal to 1% of the subscriber’s amounts invested held as of each such date. As previously disclosed, on February 15, 2017, in connection with the the Exchange Agreement and the issuance of the February Notes, the Company entered into a consent and waiver agreement with certain of its existing investors, which extended certain anti-dilution and exercise price adjustment rights granted to investors in the Company’s 2015 financing (the “Consent and Waver Agreement”). Pursuant to the Consent and Waiver Agreement, the conversion rate for the Series C Preferred Stock was set at $ 0.40 0.75 216 76,668 1,350,024 Warrants Weighted Aggregate Average Exercise Price Number Exercise Price Range Outstanding, June 30, 2014 7,237,774 $ 4.77 $ 1.00 - $ 345.00 Granted 3,552,639 1.50 1.50 Exercised - - - Cancelled - - - Expired (3,457,637) 4.84 $ 3.00 - $ 345.00 Outstanding, June 30, 2015 7,332,776 $ 3.15 $ 1.00 - $ 140.00 Granted 1,368,854 $ 1.20 $ 0.75- $ 1.50 Exercised - - - Cancelled - - - Expired (3,050) 33.77 $ 32.00 - $ 140.00 Outstanding, June 30, 2016 8,698,580 $ 2.83 $ 0.75- $ 108.00 Granted - - - Exercised - - - Cancelled - - - Expired (3,686,989) 4.74 $ 2.00 - $ 108.00 Outstanding, June 30, 2017 5,011,591 0.43 $ 0.40- $ 26.00 Warrants as liabilities at June 30, 2015 (1) 3,552,639 $ 1.50 Warrants as liabilities at June 30, 2016 (1) 4,921,493 $ 1.42 Warrants as liabilities at June 30, 2017 (1) - $ - (1) Exercise price subject to reset as disclosed in public placements of series C preferred stock section, which expired on January 27, 2017. The exercise price was reset to $0.40 on February 15, 2017. As of June 30, 2017, all of the above warrants are exercisable expiring at various dates through 2020. At June 30, 2017, the weighted-average exercise price on the above warrants was $ 0.43 In connection with the issuance of the Notes (see Note 7), the Company amended the exercise price of the warrants downward to $ 0.40 in ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging The Company recognized a one-time charge for the warrant price modification of $ 285,356 0.75 1.50 0.25 0.71 0.95 124 131 0.77 0.86

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation In December 2008, the Company adopted the 2008 Incentive Compensation Plan (the "2008 Plan"), which provides for the grant of stock options, stock grants and stock purchase rights to certain designated employees and certain other persons performing services for the Company, as designated by the board of directors. Pursuant to the 2008 Plan as amended and automatically increased as discussed below, an aggregate of 7,438,700 5 1,500,000 25 Between February 19, 2009 and February 2, 2015, the Company filed a registration statement and amendments with the SEC to register all of the 4,917,670 The terms and vesting schedules for share-based awards vary by type of grant and the employment status of the grantee. Generally, the awards vest based upon time-based conditions or achievement of specified goals and milestones. On November 18, 2014, the Company issued 392,860 237,291 85,504 51,645 70,350 47,345 81 81 Weighted Aggregate Average Exercise Price Number Exercise Price Range Outstanding, June 30, 2014 979,304 $ 9.49 $ 2.65 - $ 345.00 Granted 1,203,676 0.73 $ 0.54 - $ 0.83 Exercised - - Cancelled (552,471) 3.41 $0.83 - $ 140.00 Expired (3,590) 289.09 $ 43.00 - $ 345.00 Outstanding, June 30, 2015 1,626,919 $ 4.45 $ 0.54 - $ 140.00 Granted 485,682 $ 0.31 $ 0.22 - $ 0.50 Exercised - Cancelled (151,588) 3.99 $ 0.83 - $ 140.00 Expired (43,775) 11.02 $ 0.83 - $ 140.00 Outstanding, June 30, 2016 1,917,238 $ 3.29 $ 0.22 - $ 140.00 Granted 436,363 $ 0.22 0.22 Exercised - - Cancelled (28,140) 0.83 0.83 Expired (6,194) 60.65 $22.00 - $ 108.00 Outstanding, June 30, 2017 2,319,267 $ 2.59 Options exercisable at June 30, 2015 1,228,739 $ 5.53 Options exercisable at June 30, 2016 1,841,728 $ 3.38 Options exercisable at June 30, 2017 2,296,470 $ 2.61 Weighted-average Number of Grant-Date Options Fair Value Non-vested stock options at June 30, 2016 75,510 $ 0.76 Granted 436,363 0.22 Vested (475,593) 0.24 Forfeited (13,483) 0.60 Non-vested stock options at June 30, 2017 22,797 $ 0.60 As of June 30, 2017, the aggregate intrinsic value of stock options outstanding was $ 38,352 6.38 0 6.59 5,119,433 As of June 30, 2017 total estimated compensation expense not yet recognized related to stock option grants amounted to $ 13,769 21

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes: The Company has recurring losses and a valuation allowance against its deferred tax assets. The Company has recognized a deferred tax liability relating to the indefinite-lived intangible. The tax benefit recognized is the deferred tax benefit associated with the reduction of the indefinite-lived intangible net of any state minimum tax. As of June 30, 2017, the Company had federal net operating loss (“NOL”) carry forwards of $ 75,857,000 26,123,000 50 The Company's reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized. The Company recognized no material adjustment for unrecognized income tax benefits. Through June 30, 2017, the Company had no unrecognized tax benefits or related interest and penalties accrued. The Company files a consolidated federal income tax return. The subsidiary files separate state and local income tax returns. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a full valuation allowance against its deferred tax assets at June 30, 2017 and 2016, respectively, because the Company's management has determined that is it more likely than not that these assets will not be fully realized. The valuation allowance increased by $ 702,000 2,590,000 June 30, 2017 2016 2015 Federal income tax provision at statutory rate (34.0) % (34.0) % (34.0) % State income taxes, net of federal benefit (3.7) % (3.5) % (3.2) % Change in State Rate - % 28.7 % - % Deferred Tax Adjustment - % 17.1 % - % Goodwill Impairment - % 22.0 % 15.3 % Permanent items 12.6 % (8.4) % 0.4 % Research and development credits (0.4) % (0.7) % (3.0) % Change in valuation allowance 10.3 % (28.8) % 24.5 % Actual income tax provision (benefit) effective tax rate (15.2) % (7.6) % - % : June 30, 2017 2016 Deferred Tax Assets: Net operating loss carryforwards $ 27,315,000 $ 26,096,000 Stock-based compensation 1,415,000 1,386,000 Other 734,000 1,281,000 Deferred tax assets 29,464,000 28,763,000 Deferred Tax Liabilities: Indefinite-lived intangibles (2,200,000) (3,240,000) Deferred tax liabilities (2,200,000) (3,240,000) Less: valuation allowance (29,464,000) (28,763,000) Net deferred tax asset / (liability) $ (2,200,000) $ (3,240,000) The Company will recognize interest and penalties related to uncertain tax positions if any in income tax expense. As of June 30, 2017 and 2016, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's Statements of Operations. The Company files income tax returns in the United States, and various state jurisdictions. The federal and state income tax returns are generally subject to tax examinations for the tax years ended June 30, 2014 through June 30, 2017. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period.

Subsequent Event

Subsequent Event	12 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Event	11. Subsequent Event: On July 1, 2017, the Company exchanged 200 800,000 0.25 On July 28, 2017, the Company received aggregate proceeds of $ 1,500,000 10,000,000 0.15 The July 2017 financing was a qualified financing in accordance with the provisions of the Convertible Notes agreement. As a result, all of the Company’s Convertible Notes become mandatorily convertible on July 28, 2017, Convertible Notes with principle amount of $ 750,000 20,490 7,704,903 250,000 4,290 2,542,905 On August 24, 2017,the Company exchanged the remaining 70 700,000 0.10 On September 20, 2017, the Company exchanged the remaining 158,336 2,968,800 0.40

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Principles of consolidation	The accompanying consolidated financial statements include the accounts of Sevion Therapeutics, Inc. and the Company’s wholly owned subsidiaries, Senesco Inc., Fabrus, Inc. and Sevion Sub Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.
Management Estimates and Judgments	Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock-based compensation expense, warrant, derivatives and stock rights liabilities, the determination of the fair value of equity transactions and stock-based awards, the accounting for research and development costs, the accounting for impairment and accrued expenses.
Cash and Cash Equivalents and Short-Term Investments	The Company considers all highly liquid instruments with an original maturity of 90
Fair Value Measurements	ASC Topic 820, Fair Value Measurements, defines fair value, establishes a framework for measuring fair value and expands the related disclosure requirements. The guidance applies under other accounting pronouncements that require or permit fair value measurements. The statement indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. ASC 820 defines fair value based upon an exit price model. The Company categorizes the Company’s financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial assets recorded at fair value on the Company’s consolidated balance sheets are categorized as follows: • Level 1: Observable inputs such as quoted prices in active markets; • Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and • Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Level 3 financial instruments consist of common stock warrants with an exercise reset feature, derivatives which are conversion features in the Convertible Notes (Note 7), and common stock with embedded anti-dilutive features (“Rights”). The fair value of these warrants and Rights are estimated using a Monte Carlo valuation model, and the derivatives are valued using a weighted average Black Scholes method. The unobservable input used by the Company was the estimation of the likelihood of a reset occurring on the warrants and the anti-dilutive Rights. These estimates of the likelihood of completing an equity raise that would meet the criteria to trigger the reset provisions and anti-dilutive Rights are based on numerous factors, including the remaining term of the financial instruments and the Company’s overall financial condition. (See Note 8). The inputs used in the Black Scholes model include fair value of the common stock, interest rate, volatility of the Company’s stock and expected remaining term. The carrying value of prepaid expenses, accounts payable and accrued expenses reported in the consolidated balance sheets equal or approximate fair value due to their short maturities.
Concentrations of Credit Risk	Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains cash balances at financial institutions, which at times, exceed federally insured limits. At June 30, 2017 the Company’s cash amount did not exceed FDIC insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.
Equipment, Furniture and Fixtures, Net	Equipment, furniture and fixtures are recorded at cost, except for the equipment acquired in the acquisition of Fabrus, which is recorded at fair value. Depreciation is calculated on a straight-line basis over three to four years for office equipment, five years for lab equipment and five to seven years for furniture and fixtures. Expenditures for major renewals and improvements are capitalized, and expenditures for maintenance and repairs are charged to operations as incurred. (See Note 4).
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill is not amortized, but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company wrote off its remaining goodwill balance in the fiscal year ended June 30, 2016 as a result of an impairment review. Intangible assets include in-process research and development (IPR&D) of pharmaceutical product candidates. IPR&D are considered indefinite-lived intangible assets and are assessed for impairment annually or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss on the Company’s consolidated statement of operations. For those compounds that reach commercialization, the IPR&D assets will be amortized over their estimated useful lives. For the year ended June 30, 2017, the Company determined that there was impairment to IPR&D. (See Note 5)
Impairment of Long-lived Assets	The Company assesses the impairment in long-lived assets whenever events or circumstances indicate that their carrying value may not be recoverable. Factors the Company considers important which could trigger an impairment review include the following: • significant negative industry trends; • significant underutilization of the assets; • significant changes in how the Company uses the assets or its plans for their use; and • changes in technology and the appearance of competing technology. If a triggering event occurs and if the Company's review determines that the future undiscounted cash flows related to the groups, including these assets, will not be sufficient to recover their carrying value, the Company will reduce the carrying values of these assets down to their estimated fair value. The Company recorded impairment of long lived assets of $ 0 0 2,290,836
Net Loss per Common Share	Net Loss per Common Share Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of the Company’s common stock outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional shares of Common Stock that would have been outstanding if the potential shares of Common Stock had been issued and if the additional shares of Common Stock were dilutive. For all periods presented, basic and diluted loss per share are the same, as any additional Common Stock equivalents would be anti-dilutive. June 30, 2017 2016 Common Stock to be issued upon conversion 1,080,000 506,666 Common Stock to be issued upon conversion 2,968,801 2,350,040 Common Stock to be issued upon conversion of convertible notes and accrued interest 10,234,000 - Outstanding warrants 5,011,591 8,698,580 Outstanding options 2,319,267 1,917,238 Total potentially dilutive shares of Common Stock 21,613,659 13,472,524
Income Taxes	Income taxes are recorded in accordance with ASC Topic 740, Income Taxes, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of June 30, 2017, the Company’s tax years prior to June 30, 2014 are no longer subject to examination by the tax authorities. The Company is not currently under examination by any U.S. federal or state jurisdictions. As of June 30, 2017 and 2016, the Company does not have any significant uncertain tax positions.
Revenue Recognition	The Company has received certain nonrefundable upfront fees in exchange for the transfer of the Company’s technology to licensees. Upon delivery of the technology, the Company had no further obligations to the licensee with respect to the basic technology transferred and, accordingly, recognized revenue at that time. The Company has received certain nonrefundable upfront license fees in connection with agreements that include time-based payments and are deferred and amortized ratably over the estimated research period of the license. The Company has and may continue to receive additional payments from the Company’s licensees in the event such licensees achieve certain development or commercialization milestones in their particular field of use. Milestone payments, which are contingent upon the achievement of certain research goals, are recognized as revenue when the milestones, as defined in the particular agreement, are achieved.
Stock-based Compensation	The Company accounts for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. For stock options issued to employees, the Company estimates the grant-date fair value of each option using the Black-Scholes option-pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates, the value of the common stock and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense, net of estimated forfeitures, equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. For awards subject to both performance and service-based vesting conditions, the Company recognizes stock-based compensation expense using the straight-line recognition method when it is probable that the performance condition will be achieved. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based payments issued to non-employees are recorded at their fair values, and are periodically revalued as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. Fiscal Year Ended June 30, 2017 2016 2015 General and administrative $ 73,707 $ 130,186 $ 401,411 Research and development 6,401 26,492 79,270 Total $ 80,108 $ 156,678 $ 480,681 Fiscal Year Ended June 30, 2017 2016 2015 Risk-free interest rate (1) 1.98% .00% - 2.15% 0.02%-2.32% Expected volatility 106.00% 69%-146% 95%-153% Dividend yield None None None Expected life (in years) (2) 5.0 .08 - 8.4 0.63 - 10.0 (1) Represents the interest rate on a U.S. Treasury security with a maturity date corresponding to that of the option term. (2) Expected life for employee based stock options was estimated using the “simplified” method, as allowed under the provisions of the Securities and Exchange Commission Staff Accounting Bulletin No. 110.
Research and Development	Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses, including salaries, benefits and travel and stock-based compensation of the Company’s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct preclinical studies; other supplies; allocated facilities, depreciation and other expenses, which include rent and utilities; insurance; and costs associated with preclinical activities and regulatory operations. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be.
Recent Accounting Pronouncements Applicable to the Company	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In May 2014, the FASB issued ASU No. 2014- 09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 requires that a company recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which the company expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. In July 2015, the FASB approved a proposal to defer the effective date of the guidance until annual and interim reporting periods beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is in the process of evaluating the effect of adoption. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” (“ASU 2014-15”). ASU 2014-15 amended existing guidance related to the disclosures about an entity’s ability to continue as a going concern. These amendments are intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. These amendments provide guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the financial statement footnotes. The amendments are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. The Company has adopted this standard and there was no material impact on the consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes FASB ASC 840. All entities will be required to record operating leases on the balance sheet as assets and liabilities instead of recording only capital (finance) leases on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2017. The Company s in the process of evaluating the effect of adoption. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share Based Payment Accounting,” which is intended to simplify several aspects of accounting for share based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted. The Company does not anticipate that the adoption of this standard will have a material impact on the Company’s financial statements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments, which addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows under Accounting Standards Codification 230. The standard is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those fiscal years. Early application is permitted. The Company does not anticipate that the adoption of this standard will have a material impact on the Company’s financial statements. In July 2017, the FASB issued ASU No. 2017-11, which amends the FASB Accounting Standards Codification. Part I of ASU No. 2017-11, Accounting for Certain Financial Instruments with Down Round Features, changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The guidance is effective for reporting periods beginning after December 15, 2019 and interim periods within those fiscal years. The Company is in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements. The Company has assessed other recently issued accounting pronouncements and has determined that they do not apply.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Calculation of the weighted average number of dilutive shares of Common stock	Potentially dilutive shares of Common Stock have been excluded from the calculation of the weighted average number of dilutive shares of Common Stock as follows: June 30, 2017 2016 Common Stock to be issued upon conversion 1,080,000 506,666 Common Stock to be issued upon conversion 2,968,801 2,350,040 Common Stock to be issued upon conversion of convertible notes and accrued interest 10,234,000 - Outstanding warrants 5,011,591 8,698,580 Outstanding options 2,319,267 1,917,238 Total potentially dilutive shares of Common Stock 21,613,659 13,472,524
Stock-Based Compensation Expense and Issuance of Common Stock for Services Included in Consolidated Statements of Operations	The following table sets forth the total stock-based compensation expense and issuance of Common Stock for services included in the consolidated statements of operations for the fiscal years ended June 30, 2017, 2016 and 2015. Fiscal Year Ended June 30, 2017 2016 2015 General and administrative $ 73,707 $ 130,186 $ 401,411 Research and development 6,401 26,492 79,270 Total $ 80,108 $ 156,678 $ 480,681
Black-Scholes Option-Pricing Model Assumptions used to Estimate Fair Value of Each Warrant and Option Grant	The Company estimated the fair value of each option grant throughout the year using the Black-Scholes option-pricing model using the following assumptions: Fiscal Year Ended June 30, 2017 2016 2015 Risk-free interest rate (1) 1.98% .00% - 2.15% 0.02%-2.32% Expected volatility 106.00% 69%-146% 95%-153% Dividend yield None None None Expected life (in years) (2) 5.0 .08 - 8.4 0.63 - 10.0 (1) Represents the interest rate on a U.S. Treasury security with a maturity date corresponding to that of the option term. (2) Expected life for employee based stock options was estimated using the “simplified” method, as allowed under the provisions of the Securities and Exchange Commission Staff Accounting Bulletin No. 110.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide the assets and liabilities carried at fair value measured on a recurring basis as of June 30, 2017 and 2016: Carrying Fair Value Measurement at June 30, 2017 Value Level 1 Level 2 Level 3 Cash and cash equivalents $ 33,198 $ 33,198 $ - $ - Derivative Liability $ 1,844,974 $ - $ - $ 1,844,974 Carrying Fair Value Measurement at June 30, 2016 Value Level 1 Level 2 Level 3 Cash and cash equivalents $ 810,808 $ 810,808 $ - $ - Warrant and Stock Right Liabilities $ 956,575 $ - $ - $ 956,575
Changes in Fair Value of the Company's Level 3 Financial Instruments	The following table summarizes the changes in fair value of the Company’s Level 3 financial instruments: Fiscal Year ended June 30, 2017 2016 Beginning Balance $ 956,575 $ 2,502,047 Allocation of convertible note proceeds to derivative liability 1,101,413 - Change in fair value of derivative liability 743,561 - Issuance of common stock warrants - 559,261 Recognition of stock right - 142,854 Reclass to equity (56,066) - Change in fair value of warrant liabilities, net (249,025) (1,993,560) Change in fair value of stock right, net (651,484) (254,027) Ending Balance $ 1,844,974 $ 956,575

Equipment, Furniture and Fixt21

Equipment, Furniture and Fixtures (Tables)	12 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Equipment, Furniture and Fixtures	Equipment, Furniture and Fixtures consist of the following: June 30, 2017 2016 Laboratory Equipment $ 313,023 $ 310,523 Office Equipment 15,569 21,680 Leasehold Improvements - 10,236 Furniture and fixtures 3,700 6,920 $ 332,292 $ 349,359 Less—Accumulated depreciation (281,313) (256,805) $ 50,979 $ 92,554

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Accrued Expenses	June 30, 2017 2016 Accrued research $ - $ 66,409 Accrued professional fees 200,000 - Accrued interest 20,178 - Accrued payroll 66,200 74,240 Accrued dividends payable 10,418 9,502 Accrued other 33,505 106,225 $ 330,301 $ 256,376

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Jun. 30, 2017
Derivative Financial Instruments, Liabilities [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	February 15, 2017 March 31, 2017 May 22, 2017 June 30, 2017 Fair Value of Common Stock $ 0.15 0.25 $ 0.15 0.19 $0.26 $ 0.27 Exercise Price $ 0.10 $ 0.10 $0.10 $ 0.10 Expected Term (years) 0.17 0.75 0.17 0.63 0.33 ~ 0.50 $ 0.13 0.39 Volatility 173.5 214.5 160 178.8 155.1% ~ 174.6% 103.8 146.7 Risk Free Interest Rate 0.54 0.77 0.76 0.94 0.97% ~ 1.05% 0.84 1.09

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Fair Value Measurements, Nonrecurring	The assumptions used to value the warrants at the date of issuance and June 30, 2015 and June 30, 2016 are as follows: May/June 2015 Issuance 30-Jun-15 July 2015 Issuance 30-Jun-16 Estimated life in years 2.5 2.4 2.5 1.4 - 1.5 Risk-free interest rate (1) 0.73% 0.73% 0.91% 0.64% Volatility 115.20% 115.20% 108.60% 110.90% Dividend paid None None None None (1) Represents the interest rate on a U.S. Treasury security with a maturity date corresponding to that of the warrant term.
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award Of Warrants	Weighted Aggregate Average Exercise Price Number Exercise Price Range Outstanding, June 30, 2014 7,237,774 $ 4.77 $ 1.00 - $ 345.00 Granted 3,552,639 1.50 1.50 Exercised - - - Cancelled - - - Expired (3,457,637) 4.84 $ 3.00 - $ 345.00 Outstanding, June 30, 2015 7,332,776 $ 3.15 $ 1.00 - $ 140.00 Granted 1,368,854 $ 1.20 $ 0.75- $ 1.50 Exercised - - - Cancelled - - - Expired (3,050) 33.77 $ 32.00 - $ 140.00 Outstanding, June 30, 2016 8,698,580 $ 2.83 $ 0.75- $ 108.00 Granted - - - Exercised - - - Cancelled - - - Expired (3,686,989) 4.74 $ 2.00 - $ 108.00 Outstanding, June 30, 2017 5,011,591 0.43 $ 0.40- $ 26.00 Warrants as liabilities at June 30, 2015 (1) 3,552,639 $ 1.50 Warrants as liabilities at June 30, 2016 (1) 4,921,493 $ 1.42 Warrants as liabilities at June 30, 2017 (1) - $ - (1) Exercise price subject to reset as disclosed in public placements of series C preferred stock section, which expired on January 27, 2017. The exercise price was reset to $0.40 on February 15, 2017.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Activity	Stock option activity under the 2008 Plan and 1998 Plan is summarized as follows: Weighted Aggregate Average Exercise Price Number Exercise Price Range Outstanding, June 30, 2014 979,304 $ 9.49 $ 2.65 - $ 345.00 Granted 1,203,676 0.73 $ 0.54 - $ 0.83 Exercised - - Cancelled (552,471) 3.41 $0.83 - $ 140.00 Expired (3,590) 289.09 $ 43.00 - $ 345.00 Outstanding, June 30, 2015 1,626,919 $ 4.45 $ 0.54 - $ 140.00 Granted 485,682 $ 0.31 $ 0.22 - $ 0.50 Exercised - Cancelled (151,588) 3.99 $ 0.83 - $ 140.00 Expired (43,775) 11.02 $ 0.83 - $ 140.00 Outstanding, June 30, 2016 1,917,238 $ 3.29 $ 0.22 - $ 140.00 Granted 436,363 $ 0.22 0.22 Exercised - - Cancelled (28,140) 0.83 0.83 Expired (6,194) 60.65 $22.00 - $ 108.00 Outstanding, June 30, 2017 2,319,267 $ 2.59 Options exercisable at June 30, 2015 1,228,739 $ 5.53 Options exercisable at June 30, 2016 1,841,728 $ 3.38 Options exercisable at June 30, 2017 2,296,470 $ 2.61
Non-vested Stock Option Activity	Non-vested stock option activity under the Plan is summarized as follows: Weighted-average Number of Grant-Date Options Fair Value Non-vested stock options at June 30, 2016 75,510 $ 0.76 Granted 436,363 0.22 Vested (475,593) 0.24 Forfeited (13,483) 0.60 Non-vested stock options at June 30, 2017 22,797 $ 0.60

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Reconciliation of Effective Income Tax Rate to Federal Statutory Rate	The reconciliation of the effective income tax rate to the federal statutory rate is as follows: June 30, 2017 2016 2015 Federal income tax provision at statutory rate (34.0) % (34.0) % (34.0) % State income taxes, net of federal benefit (3.7) % (3.5) % (3.2) % Change in State Rate - % 28.7 % - % Deferred Tax Adjustment - % 17.1 % - % Goodwill Impairment - % 22.0 % 15.3 % Permanent items 12.6 % (8.4) % 0.4 % Research and development credits (0.4) % (0.7) % (3.0) % Change in valuation allowance 10.3 % (28.8) % 24.5 % Actual income tax provision (benefit) effective tax rate (15.2) % (7.6) % - %
Deferred Income Tax Assets	The principal components of deferred income tax assets consist of the following : June 30, 2017 2016 Deferred Tax Assets: Net operating loss carryforwards $ 27,315,000 $ 26,096,000 Stock-based compensation 1,415,000 1,386,000 Other 734,000 1,281,000 Deferred tax assets 29,464,000 28,763,000 Deferred Tax Liabilities: Indefinite-lived intangibles (2,200,000) (3,240,000) Deferred tax liabilities (2,200,000) (3,240,000) Less: valuation allowance (29,464,000) (28,763,000) Net deferred tax asset / (liability) $ (2,200,000) $ (3,240,000)

Principal Business Activity - A

Principal Business Activity - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Jul. 28, 2017	May 31, 2017	Jun. 30, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2014
Accumulated deficit				$ 121,824,326
Cash and Cash Equivalents, at Carrying Value			$ 3,334,626	33,198	$ 810,808	$ 6,111,340
Debt Instrument, Covenant Description		12,000,000
Business Acquisition, Transaction Costs				$ 312,260
Eloxx Pharmaceuticals Ltd., [Member]
Equity Method Investment, Aggregate Cost		$ 12,000,000
University of Waterloo, Research Agreement [Member]
Termination Benefits And Associated Employee Costs			$ 47,000
Opko Health Inc [Member]
Proceeds from Issuance of Common Stock	$ 1,500,000

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Summary Of Significant Accounting Policies [Line Items]
Maturity period of all highly liquid instruments at the time of purchase to be cash equivalents (in days)	90 days
Finite-lived Intangible Assets, Written off	$ 0	$ 0	$ (2,290,836)	$ 2,290,836

Calculation of Weighted Average

Calculation of Weighted Average Number of Dilutive Shares of Common Stock (Detail) - shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Summary Of Significant Accounting Policies [Line Items]
Common Stock to be issued upon conversion	21,613,659	13,472,524
Convertible Debt Securities [Member]
Summary Of Significant Accounting Policies [Line Items]
Common Stock to be issued upon conversion	10,234,000	0
Series A Preferred stock
Summary Of Significant Accounting Policies [Line Items]
Common Stock to be issued upon conversion	1,080,000	506,666
Series C Preferred Stock
Summary Of Significant Accounting Policies [Line Items]
Common Stock to be issued upon conversion	2,968,801	2,350,040
Outstanding options
Summary Of Significant Accounting Policies [Line Items]
Common Stock to be issued upon conversion	2,319,267	1,917,238
Outstanding warrants
Summary Of Significant Accounting Policies [Line Items]
Common Stock to be issued upon conversion	5,011,591	8,698,580

Stock-Based Compensation Expens

Stock-Based Compensation Expense and Issuance of Common Stock for Services Included in Consolidated Statements of Operations (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Summary Of Significant Accounting Policies [Line Items]
Stock-based compensation expense	$ 80,108	$ 156,678	$ 480,681
General and administrative
Summary Of Significant Accounting Policies [Line Items]
Stock-based compensation expense	73,707	130,186	401,411
Research and development
Summary Of Significant Accounting Policies [Line Items]
Stock-based compensation expense	$ 6,401	$ 26,492	$ 79,270

Black-Scholes Option-Pricing Mo

Black-Scholes Option-Pricing Model Assumptions used to Estimate Fair Value of Each Warrant and Option Grant (Detail)		12 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	[1]	1.98%
Expected volatility		106.00%
Expected volatility, minimum			69.00%	95.00%
Expected volatility, maximum			146.00%	153.00%
Dividend yield		0.00%	0.00%	0.00%
Expected life (in years)	[2]	5 years
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	[1]		0.00%	0.02%
Expected life (in years)	[2]		29 days	7 months 17 days
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, maximum	[1]		2.15%	2.32%
Expected life (in years)	[2]		8 years 4 months 24 days	10 years
[1]	Represents the interest rate on a U.S. Treasury security with a maturity date corresponding to that of the option term.
[2]	Expected life for employee based stock options was estimated using the “simplified” method, as allowed under the provisions of the Securities and Exchange Commission Staff Accounting Bulletin No. 110.

Assets and Liabilities at Fair

Assets and Liabilities at Fair Value Measured on Recurring Basis (Detail) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant and Stock Right Liabilities	$ 0	$ 956,575	$ 2,502,047
Fair Value Measurements Recurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	33,198	810,808
Warrant and Stock Right Liabilities		956,575
Derivative Liability	1,844,974
Level 1 | Fair Value Measurements Recurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Fair Value	33,198	810,808
Warrant and Stock Right Liabilities		0
Derivative Liability	0
Level 2 | Fair Value Measurements Recurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Fair Value	0	0
Warrant and Stock Right Liabilities		0
Derivative Liability	0
Level 3 | Fair Value Measurements Recurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Fair Value	0	0
Warrant and Stock Right Liabilities		$ 956,575
Derivative Liability	$ 1,844,974

Changes in Fair Value of the Co

Changes in Fair Value of the Company's Financial Instruments (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Beginning Balance	$ 956,575	$ 2,502,047
Allocation of convertible note proceeds to derivative liability	1,101,413	0
Change in fair value of derivative liability	743,561	0
Issuance of common stock warrants	0	559,261	$ 1,742,703
Recognition of stock right	0	142,854	775,062
Reclass to equity	(56,066)	0
Change in fair value of warrant liabilities, net	(249,025)	(1,993,560)	(3,313)
Change in fair value of stock right, net	(651,484)	(254,027)	(12,405)
Ending Balance	$ 0	$ 956,575	$ 2,502,047

Equipment, Furniture and Fixt34

Equipment, Furniture and Fixtures - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciation	$ 44,075	$ 93,394	$ 152,097
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent	$ 19,567

Equipment, Furniture and Fixt35

Equipment, Furniture and Fixtures (Detail) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 332,292	$ 349,359
Less—Accumulated depreciation	(281,313)	(256,805)
Property, Plant and Equipment, Net	50,979	92,554
Laboratory Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	313,023	310,523
Office Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	15,569	21,680
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	0	10,236
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,700	$ 6,920

Intangible assets - Additional

Intangible assets - Additional Information (Detail) - USD ($)	1 Months Ended						12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Oct. 31, 2014	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Impairment Of Intangible Assets Finitelived			$ 1,000,000				$ 0	$ 5,780,951	$ 8,121,966
Acquired Research And Development					$ 9,800,000		5,500,000	8,100,000
Finite-Lived Patents, Gross					283,393
Goodwill					13,902,917
Goodwill, Impairment Loss					$ 8,121,966		0	5,780,951	8,121,966
Write-Off Of Prepaid Research Supplies							0	0	669,750
Asset Impairment Charges			2,981,000	$ 2,800,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)			$ 8,800,000
Impairment Of Intangible Assets Excluding Goodwill							$ 2,600,000	1,700,000	$ 2,290,836
Acquired Research And Development [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment Of Intangible Assets Finitelived								$ 700,000
Impairment Of Intangible Assets Excluding Goodwill	$ 1,000,000	$ 1,600,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment Of Intangible Assets Finitelived						$ 2,290,836

Accrued Expenses (Detail)

Accrued Expenses (Detail) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Accounts Payable And Accrued Liabilities [Line Items]
Accrued research	$ 0	$ 66,409
Accrued professional fees	200,000	0
Accrued interest	20,178	0
Accrued payroll	66,200	74,240
Accrued dividends payable	10,418	9,502
Accrued other	33,505	106,225
Accrued Liabilities, Current	$ 330,301	$ 256,376

Notes Payable- Additional Infor

Notes Payable- Additional Information (Detail) - USD ($)	1 Months Ended
	Jun. 30, 2017	May 31, 2017	Feb. 15, 2017	Jun. 02, 2017	Nov. 10, 2016
Scenario One [Member]
Percentage of Ownership Interests	9.99%
Maximum [Member]
Percentage of Ownership Interests	4.99%
Convertible Notes Payable [Member]
Debt Instrument, Face Amount				$ 100,000
Debt Conversion, Converted Instrument, Shares Issued	1,032,219
Interest Payable				$ 3,222
Gain (Loss) on Extinguishment of Debt	$ 54,000
May 2017 Notes [Member]
Derivative, Loss on Derivative		$ 212,000
Opko Health Inc [Member] | Convertible Notes Payable [Member]
Debt Instrument, Face Amount			$ 800,000		$ 300,000
Debt Instrument, Interest Rate, Stated Percentage			6.00%		5.00%
Debt Instrument, Convertible, Terms of Conversion Feature			The Notes provide for mandatory conversion: (a) if the Company enters into a transaction or series of transactions for an aggregate sale price of at least One Million Dollars ($1,000,000) of the Company’s capital stock (referred to as the “Qualified Financing”) then the outstanding principal balance and accrued but unpaid interest on the Notes will automatically convert into such capital stock sold in the Qualified Financing at a conversion price equal to the lesser of (i) the price per share paid by investors at the close of the Qualified Financing or (ii) $0.10 (the “Conversion Price”); or (b) upon a sale of all or substantially all of the Company’s assets, whether by sale, acquisition or merger, the outstanding principal balance and accrued but unpaid interest on the Notes will automatically convert at the Conversion Price into shares of Common Stock or such other securities on terms and conditions agreed upon by the Company and the holders of a majority of the outstanding principal amount of the Notes.
Debt Instrument, Convertible, Conversion Price			$ 0

Notes Payable(Detail)

Notes Payable(Detail) - $ / shares		1 Months Ended				12 Months Ended
		Jun. 30, 2017	May 22, 2017	Mar. 31, 2017	Feb. 15, 2017	Jun. 30, 2016	Jun. 30, 2015
Fair Value Assumptions, Expected Term							2 years 4 months 24 days
Fair Value Assumptions, Expected Volatility Rate						110.90%	115.20%
Fair Value Assumptions, Risk Free Interest Rate	[1]					0.64%	0.73%
Maximum [Member]
Fair Value Assumptions, Expected Term						1 year 6 months
Minimum [Member]
Fair Value Assumptions, Expected Term						1 year 4 months 24 days
Derivative Financial Instruments, Liabilities [Member]
Share Price		$ 0.27	$ 0.26
Fair Value Assumptions, Exercise Price		$ 0.10	$ 0.10	$ 0.10	$ 0.10
Derivative Financial Instruments, Liabilities [Member] | Maximum [Member]
Share Price				$ 0.19	$ 0.25
Fair Value Assumptions, Expected Term		4 months 20 days	6 months	7 months 17 days	9 months
Fair Value Assumptions, Expected Volatility Rate		146.70%	174.60%	178.80%	214.50%
Fair Value Assumptions, Risk Free Interest Rate		1.09%	1.05%	0.94%	0.77%
Derivative Financial Instruments, Liabilities [Member] | Minimum [Member]
Share Price				$ 0.15	$ 0.15
Fair Value Assumptions, Expected Term		1 month 17 days	3 months 29 days	2 months 1 day	2 months 1 day
Fair Value Assumptions, Expected Volatility Rate		103.80%	155.10%	160.00%	173.50%
Fair Value Assumptions, Risk Free Interest Rate		0.84%	0.97%	0.76%	0.54%
[1]	Represents the interest rate on a U.S. Treasury security with a maturity date corresponding to that of the warrant term.

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 27, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2017	Feb. 15, 2017
Preferred Stock Stated Value Per Share		$ 1,000
Preferred Stock, Dividend Rate, Percentage		10.00%
Preferred Stock, Dividend Payment Terms		If the dividends are paid in shares of Common Stock, such shares will be priced at the lower of 90% of the average volume weighted-average price for the 20 trading days immediately preceding the payment date.
Stock Conversion Price Per Share		$ 0.75
Stock Issued During Period, Value, New Issues			$ 1,152,397	$ 4,827,569
Stock Issued During Period Shares Stock Dividend		212,482	108,576	59,500
Stock Issued During Period, Value, Stock Dividend		$ 42,598	$ 40,286	$ 56,583
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.40
Common stock proceeds to warrants		$ 0	559,261	1,742,703
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net		$ 249,025	1,993,560	3,313
Shares Issued, Price Per Share		$ 0.01
Common Stock Proceeds To Stock Rights		$ 0	142,854	775,062
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments		$ 651,484	254,027	12,405
Other Commitments, Description		The agreement included a penalty of 1% per month of the investor’s investment, payable in cash, for every 30 day period up to a maximum of 6% for failure to comply with the terms of the agreement.In the event the listing is not continuously maintained for five years after the closing date, on each monthly anniversary of each such listing default date until the applicable listing default is cured, the Company would pay to each subscriber an amount in cash, as partial liquidated damages equal to 1% of the subscriber’s amounts invested held as of each such date.
Deemed Dividends On Preferred Stock			0	0
Common stock proceeds to warrants and Conversion		$ 0	$ 135,701	$ 790,507
Fair Value Adjustment of Warrants		$ 285,356
Fair Value Assumptions, Expected Term				2 years 4 months 24 days
Fair Value Assumptions, Expected Volatility Rate			110.90%	115.20%
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price		$ 2.61	$ 3.38	$ 5.53
Reclassification Of Warrants To Equity		$ 56,066	$ 0	$ 0
Public Placements of Common Stock and Warrants
Issuance Of Common Stock And Warrants Price Per Share			$ 0.75
Stock Issued During Period, Shares, New Issues			666,667	2,358,370
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1.50
Common stock proceeds to warrants			$ 559,261	$ 1,742,703
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net		$ 249,025	$ 1,993,560	3,313
Maximum
Percentage of Ownership Interests		4.99%
Fair Value Assumptions, Expected Term			1 year 6 months
Minimum [Member]
Fair Value Assumptions, Expected Term			1 year 4 months 24 days
Preferred Stock
Stock Conversion Price Per Share		$ 32
Conversion of Stock, Description		The conversion price was subject to adjustment if the Company sells or grants any Common Stock or Common Stock equivalents, subject to certain exclusions, at an effective price per share that was lower than the conversion price of the Series A Convertible Preferred Stock. As a result of multiple issuances of shares of common stock and the Exchange Agreement (defined below), the initial conversion prices had been adjusted from $32.00 per share to $0.25 per share.
Stock Issued During Period, Value, New Issues			$ 667	$ 2,358
Stock Issued During Period, Shares, New Issues			66,667	235,837
Deemed Dividends On Preferred Stock			$ 0	$ 0
Common stock
Stock Issued During Period, Value, New Issues			$ 9,600	$ 47,470
Stock Issued During Period, Shares, New Issues			959,996	4,746,952
Deemed Dividends On Preferred Stock		$ 0	$ 0	$ 0
Common stock | Public Placements of Common Stock and Warrants
Stock Issued During Period, Shares, New Issues			1,626,663	4,746,952
Warrant
Share Price		$ 0.25
Class of Warrant or Right, Exercise Price of Warrants or Rights		1.50
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price		0.43
Warrant | Maximum
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.50
Fair Value Assumptions, Expected Term		11 months 12 days
Fair Value Assumptions, Expected Volatility Rate		131.00%
Fair Value Inputs, Discount Rate		0.86%
Warrant | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.75
Fair Value Assumptions, Expected Term		8 months 16 days
Fair Value Assumptions, Expected Volatility Rate		124.00%
Fair Value Inputs, Discount Rate		0.77%
Series A Preferred stock
Convertible Preferred Stock, Shares Issued upon Conversion		270				440,000
Deemed Dividends On Preferred Stock		$ 138,000
Preferred Stock, Shares Outstanding		270	380			110
Convertible Preferred Stock Exchange Conversion Price						$ 0.25
Series C Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion		1,350,024	666,667
Preferred Stock, Dividend Rate, Percentage		0.00%
Stock Conversion Price Per Share		$ 0.75
Percentage of Ownership Interests		4.99%
Preferred Stock, Dividends Per Share, Declared		$ 7.50
Deemed Dividends On Preferred Stock		$ 216,000
Preferred Stock, Shares Outstanding		158,336	235,004
Conversion of Stock, Shares Converted		76,668
Convertible Preferred Stock Exchange Conversion Price		$ 0.40			$ 0.75
Series C Preferred Stock [Member] | Public Placements of Common Stock and Warrants
Convertible Preferred Stock, Shares Issued upon Conversion				2,358,370
Stock Issued During Period, Value, New Issues			$ 1,219,997	$ 5,328,966
Stock Issued During Period, Shares, New Issues			66,667	235,837
Payments of Stock Issuance Costs				$ 501,397
Convertible Preferred Stock Warrants Issued Upon Conversion			813,332	3,552,640
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75	$ 0.75
Number Of Warrants Issued	555,552
Placement Agent Warrants [Member] | Public Placements of Common Stock and Warrants
Payments of Stock Issuance Costs			$ 67,600

Stockholders' Equity (Detail)

Stockholders' Equity (Detail) - $ / shares		1 Months Ended	12 Months Ended
		Jul. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
Estimated life in years				2 years 4 months 24 days
Risk-free interest rate	[1]		0.64%	0.73%
Volatility			110.90%	115.20%
Dividend paid
Maximum [Member]
Estimated life in years			1 year 6 months
Minimum [Member]
Estimated life in years			1 year 4 months 24 days
Date of Issuance [Member]
Estimated life in years		2 years 6 months		2 years 6 months
Risk-free interest rate	[1]	0.91%		0.73%
Volatility		108.60%		115.20%
Dividend paid
[1]	Represents the interest rate on a U.S. Treasury security with a maturity date corresponding to that of the warrant term.

Warrant activity (Detail)

Warrant activity (Detail) - $ / shares		12 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Exercise Price Range
Granted		$ 0		$ 1.50
Exercised		0	$ 0	0
Cancelled		0	0	0
Maximum [Member]
Exercise Price Range
Beginning Balance		108	140	345
Granted			1.50
Expired		108	140	345
Ending Balance		26	108	140
Minimum [Member]
Exercise Price Range
Beginning Balance		0.75	1	1
Granted			0.75
Expired		2	32	3
Ending Balance		$ 0.40	$ 0.75	$ 1
Warrant [Member]
Aggregate Number
Beginning Balance		8,698,580	7,332,776	7,237,774
Granted		0	1,368,854	3,552,639
Exercised		0	0	0
Cancelled		0	0	0
Expired		(3,686,989)	(3,050)	(3,457,637)
Ending Balance		5,011,591	8,698,580	7,332,776
Warrants as liabilities	[1]	0	4,921,493	3,552,639
Weighted Average Exercise Price
Beginning Balance		$ 2.83	$ 3.15	$ 4.77
Granted		0	1.20	1.50
Exercised		0	0	0
Cancelled		0	0	0
Expired		4.74	33.77	4.84
Ending Balance		0.43	2.83	3.15
Warrants as liabilities	[1]	$ 0	$ 1.42	$ 1.50
[1]	Exercise price subject to reset as disclosed in public placements of series C preferred stock section, which expired on January 27, 2017. The exercise price was reset to $0.40 on February 15, 2017.

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 18, 2014	Jun. 30, 2017	Jun. 30, 2015	Feb. 19, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued	392,860	436,363
Stock option outstanding intrinsic value		$ 38,352
Option outstanding weighted average remaining term		6 years 4 months 17 days
Exercisable aggregate intrinsic value		$ 0
Weighted average option exercisable remaining life		6 years 7 months 2 days
Shares available for future stock option grant		5,119,433
Stock based compensation expense related to stock options, not yet recognized, period of recognition		21 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 47,345
Probability to achieve employee target goals		81.00%	81.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 13,769
Stock Granted, Value, Share-based Compensation, Gross	$ 237,291
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	85,504
Stock Issued During Period, Value, Share-based Compensation, Forfeited	$ 51,645
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	70,350	475,593
Share Reserve Increase		5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum		25.00%
2008 Incentive Compensation Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance		7,438,700
Annual Increase In Aggregate Number Of Shares Reserved For Future Issuance		1,500,000
Share Registration Statement Shares Of Common Stock To Be Registered				4,917,670

Stock-Based Compensation Stock

Stock-Based Compensation Stock Option Activity (Detail) - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Aggregate Number
Beginning Balance	1,917,238	1,626,919	979,304
Granted	436,363	485,682	1,203,676
Exercised	0	0	0
Cancelled	(28,140)	(151,588)	(552,471)
Expired	(6,194)	(43,775)	(3,590)
Ending Balance	2,319,267	1,917,238	1,626,919
Options exercisable at end of Period	2,296,470	1,841,728	1,228,739
Weighted Average Exercise Price
Beginning Balance	$ 3.29	$ 4.45	$ 9.49
Granted	0.22	0.31	0.73
Exercised	0
Cancelled	0.83	3.99	3.41
Expired	60.65	11.02	289.09
Ending Balance	2.59	3.29	4.45
Options exercisable at end of Period	2.61	3.38	5.53
Exercise Price Range
Granted	0.22
Cancelled	0.83
Maximum [Member]
Exercise Price Range
Beginning Balance	140	140	345
Granted		0.50	0.83
Cancelled		140	140
Expired	108	140	345
Ending Balance		140	140
Minimum [Member]
Exercise Price Range
Beginning Balance	0.22	0.54	2.65
Granted		0.22	0.54
Cancelled		0.83	0.83
Expired	$ 22	0.83	43
Ending Balance		$ 0.22	$ 0.54

Non-vested stock option activit

Non-vested stock option activity under Plan (Detail) - $ / shares	1 Months Ended	12 Months Ended
	Nov. 18, 2014	Jun. 30, 2017
Number of Options
Beginning Balance		75,510
Options issued	392,860	436,363
Vested	(70,350)	(475,593)
Forfeited		(13,483)
Ending Balance		22,797
Weighted-average Grant-Date Fair Value
Beginning Balance		$ 0.76
Granted		0.22
Vested		0.24
Forfeited		0.6
Ending Balance		$ 0.60

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Income Tax [Line Items]
Equity Method Investment, Ownership Percentage	50.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$ 702,000	$ 2,590,000
Federal
Income Tax [Line Items]
Operating Loss Carryforwards	$ 75,857,000
Operating Loss Carryforwards Expiration Period	expire in 2019
State
Income Tax [Line Items]
Operating Loss Carryforwards	$ 26,123,000
Operating Loss Carryforwards Expiration Period	expire at various dates starting in 2031

Reconciliation of Effective Inc

Reconciliation of Effective Income Tax Rate to Federal Statutory Rate (Detail)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Reconciliation Of Effective Income Tax Rate [Line Items]
Federal income tax provision at statutory rate	(34.00%)	(34.00%)	(34.00%)
State income taxes, net of federal benefit	(3.70%)	(3.50%)	(3.20%)
Change in State Rate	0.00%	28.70%	0.00%
Deferred Tax Adjustment	0.00%	17.10%	0.00%
Goodwill Impairment	0.00%	22.00%	15.30%
Permanent items	12.60%	(8.40%)	0.40%
Research and development credits	(0.40%)	(0.70%)	(3.00%)
Change in valuation allowance	10.30%	(28.80%)	24.50%
Actual income tax provision (benefit) effective tax rate	(15.20%)	(7.60%)	0.00%

Deferred Income Tax Asset (Deta

Deferred Income Tax Asset (Detail) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Deferred Tax Assets [Line Items]
Net operating loss carryforwards	$ 27,315,000	$ 26,096,000
Stock-based compensation	1,415,000	1,386,000
Other	734,000	1,281,000
Deferred tax assets	29,464,000	28,763,000
Deferred Tax Liabilities:
Indefinite-lived intangibles	(2,200,000)	(3,240,000)
Deferred tax liabilities	(2,200,000)	(3,240,000)
Less: valuation allowance	(29,464,000)	(28,763,000)
Net deferred tax asset / (liability)	$ (2,200,000)	$ (3,240,000)

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - USD ($)	1 Months Ended						12 Months Ended
	Oct. 31, 2017	Sep. 20, 2017	Aug. 24, 2017	Jul. 31, 2017	Jul. 28, 2017	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Sep. 28, 2017	Jun. 02, 2017
Subsequent Event [Line Items]
Shares Issued, Price Per Share						$ 0.01	$ 0.01
Opko Health Inc [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Common Stock					$ 1,500,000
Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount											$ 100,000
Interest Payable											$ 3,222
Debt Conversion, Converted Instrument, Shares Issued						1,032,219
Convertible Notes Payable [Member] | Scenario, Forecast [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 250,000
Interest Payable	$ 4,290
Debt Conversion, Converted Instrument, Shares Issued	2,542,905
Series C Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted							76,668
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues								959,996	4,746,952
Subsequent Event [Member] | Opko Health Inc [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Common Stock					$ 1,500,000
Stock Issued During Period, Shares, New Issues					10,000,000
Shares Issued, Price Per Share										$ 0.15
Subsequent Event [Member] | Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount										$ 750,000
Interest Payable										$ 20,490
Debt Conversion, Converted Instrument, Shares Issued					7,704,903
Subsequent Event [Member] | Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted			70	200
Preferred Stock,Conversion Price Per Share		$ 0.40	$ 0.10	$ 0.25
Subsequent Event [Member] | Series C Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted		158,336
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, New Issuance		2,968,800	700,000	800,000